[{"address1": "11025 North Torrey Pines Road", "address2": "Suite 140", "city": "La Jolla", "state": "CA", "zip": "92037", "country": "United States", "phone": "858-795-4220", "website": "https://inhibrx.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.", "fullTimeEmployees": 166, "companyOfficers": [{"maxAge": 1, "name": "Mr. Mark Paul Lappe", "age": 56, "title": "CEO, President & Chairman", "yearBorn": 1967, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kelly Devine Deck B.S., CPA, M.S.", "age": 43, "title": "Executive VP, CFO & Treasurer", "yearBorn": 1980, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ashraf  Amanullah Ph.D.", "age": 55, "title": "Executive VP, Chief Technical Operations Officer", "yearBorn": 1968, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Brendan P. Eckelman Ph.D.", "age": 44, "title": "Executive VP & Chief Scientific Officer", "yearBorn": 1979, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Leah  Pollema J.D.", "title": "VP & General Counsel", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Charbel  Helaihel Pharm.D.", "title": "Vice President of Marketing & Commercial Planning", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jeffrey J. Jensen", "title": "Executive VP & Chief Clinical Operations Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Josep  Garcia Ph.D.", "title": "Executive VP & Chief Clinical Development Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Matly M.B.A.", "title": "Executive VP and Chief Commercial & Business Development Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Carlos  Bais Ph.D.", "title": "Executive Vice President of Translational Sciences", "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 2, "previousClose": 16.04, "open": 15.98, "dayLow": 15.6701, "dayHigh": 16.09, "regularMarketPreviousClose": 16.04, "regularMarketOpen": 15.98, "regularMarketDayLow": 15.6701, "regularMarketDayHigh": 16.09, "trailingPE": 0.1349714, "forwardPE": -1.4542159, "volume": 61700, "regularMarketVolume": 61700, "averageVolume": 165480, "averageVolume10days": 128470, "averageDailyVolume10Day": 128470, "bid": 15.96, "ask": 16.07, "bidSize": 100, "askSize": 100, "marketCap": 232193456, "fiftyTwoWeekLow": 10.8, "fiftyTwoWeekHigh": 18.95, "priceToSalesTrailing12Months": 137.6369, "fiftyDayAverage": 13.4143, "twoHundredDayAverage": 13.965703, "currency": "USD", "enterpriseValue": 7504500, "profitMargins": 1019.7422, "floatShares": 7822489, "sharesOutstanding": 14475900, "sharesShort": 752846, "sharesShortPriorMonth": 732578, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.051999997, "heldPercentInsiders": 0.23546, "heldPercentInstitutions": 0.67227, "shortRatio": 7.73, "bookValue": 15.154, "priceToBook": 1.0584664, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": 1720305024, "trailingEps": 118.84, "forwardEps": -11.03, "enterpriseToRevenue": 4.448, "enterpriseToEbitda": -0.025, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "INBX", "underlyingSymbol": "INBX", "shortName": "Inhibrx Biosciences, Inc.", "longName": "Inhibrx Biosciences, Inc.", "firstTradeDateEpochUtc": 1717507800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "65117bf8-50e3-3c16-a5dd-bee97e3c0678", "gmtOffSetMilliseconds": -14400000, "currentPrice": 16.04, "targetHighPrice": 11.0, "targetLowPrice": 11.0, "targetMeanPrice": 11.0, "targetMedianPrice": 11.0, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 1, "totalCash": 226860000, "totalCashPerShare": 15.672, "ebitda": -300927008, "totalDebt": 2171000, "quickRatio": 5.845, "currentRatio": 6.198, "totalRevenue": 1687000, "debtToEquity": 0.99, "revenuePerShare": 0.117, "operatingCashflow": -167172000, "revenueGrowth": 2.333, "operatingMargins": -1608.98, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]